BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
Elpiscience will receive up to US $37 million, including the upfront payment and license option fees
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Full approval will depend on verification of clinical benefit in a confirmatory trial
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Subscribe To Our Newsletter & Stay Updated
